Frontage Holdings Corporation
Research Frontage Holdings Corporation (1521.HK) on Bullrun: market cap HKD 2.32B, P/E 28.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1521.HK
- ExchangeHK
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 2.32B
- P/E28.5
- Financial periodFY2025
- RevenueUSD 256.69M
- Revenue growth0.7%
- Net incomeUSD 6.79M
- Free cash flowUSD 32.27M
- Gross margin27.0%
Valuation Snapshot
latest market cap is HKD 2.32B; P/E is 28.5.
Peer valuation comparison
Latest P/E is 28.5x versus a Healthcare sector median of 21.74x (31.1% above).
Latest P/E is 28.5x versus a United States median of 23.81x (19.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 256.69M | USD 6.79M | USD 32.27M | 27.0% | 0 | USD 36.30M | USD 127.62M | USD 346.79M |
| FY2024 | USD 254.91M | USD 791.00K | USD 14.75M | 27.4% | 0 | USD 44.09M | USD 154.37M | USD 333.01M |
| FY2023 | USD 259.86M | USD 10.81M | USD 18.59M | 30.2% | 0.01 | USD 53.19M | USD 145.10M | USD 342.50M |
| FY2022 | USD 250.36M | USD 25.74M | USD 14.40M | 35.6% | 0.01 | USD 87.43M | USD 118.19M | USD 333.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.32B | 28.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Frontage Holdings Corporation
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Frontage Holdings Corporation's market cap?
Frontage Holdings Corporation's market capitalization is HKD 2.32B.
What is Frontage Holdings Corporation's P/E ratio?
Frontage Holdings Corporation's price-to-earnings (P/E) ratio is 28.5.
What does Frontage Holdings Corporation do?
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening.